Zacks: Analysts Expect CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Will Post Earnings of -$0.21 Per Share

Analysts forecast that CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) will announce earnings of ($0.21) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for CNS Pharmaceuticals’ earnings. CNS Pharmaceuticals reported earnings per share of ($0.12) during the same quarter last year, which would suggest a negative year over year growth rate of 75%. The business is scheduled to report its next quarterly earnings results on Thursday, November 11th.

According to Zacks, analysts expect that CNS Pharmaceuticals will report full year earnings of ($0.84) per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will post earnings of ($0.68) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for CNS Pharmaceuticals.

CNS Pharmaceuticals (NASDAQ:CNSP) last announced its quarterly earnings results on Thursday, August 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01.

A number of research firms have recently weighed in on CNSP. Alliance Global Partners began coverage on CNS Pharmaceuticals in a report on Friday, August 27th. They set a “buy” rating and a $4.00 target price for the company. Zacks Investment Research raised CNS Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 1st.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. bought a new position in shares of CNS Pharmaceuticals in the first quarter worth $28,000. Jane Street Group LLC bought a new position in shares of CNS Pharmaceuticals in the first quarter worth $33,000. State Street Corp bought a new position in shares of CNS Pharmaceuticals in the second quarter worth $35,000. Commonwealth Equity Services LLC bought a new position in shares of CNS Pharmaceuticals in the second quarter worth $39,000. Finally, Northern Trust Corp bought a new position in shares of CNS Pharmaceuticals in the first quarter worth $77,000. Institutional investors own 4.99% of the company’s stock.

CNSP opened at $1.53 on Tuesday. CNS Pharmaceuticals has a fifty-two week low of $1.39 and a fifty-two week high of $4.46. The company has a market capitalization of $42.02 million, a P/E ratio of -2.55 and a beta of 2.34. The stock has a fifty day moving average of $1.67 and a 200-day moving average of $1.97.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.

Read More: Is it better to buy a fund with a higher or lower NAV?

Get a free copy of the Zacks research report on CNS Pharmaceuticals (CNSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.